Market Research Blog

Increasing acceptance of therapeutic nuclear medicines (or radiopharmaceuticals) among industry experts will remain a prominent factor encouraging their adoption. Though associated with a negligible risk factor, radiopharmaceuticals are likely to witness growing recommendation owing to no proven significant adverse effects.

In the backdrop of the growing criticality of a more reliable, safer, and lesser harmful line of treatment for cancers, therapeutic nuclear medicines are being increasingly perceived as the potential treatment for cancer patients. Moreover, consistently surging instances of bone metastases further supports adoption growth, in the therapeutic nuclear medicines market.

Just-under 10% Annual Growth Projected for Radiopharmaceuticals Adoption

A recent market research intelligence by Future Market Insights focuses on the deep-dive evaluation of global therapeutic nuclear medicines landscape, emphasizing the analysis of the most influential factors responsible for surging acceptance of radiopharmaceuticals in treating a range of cancers and a few other chronic conditions.

The study projects robust progress for the global radiopharmaceuticals market in coming years, reportedly driven by remarkable adoption in the treatment of prostate cancer. In 2019, the global demand for therapeutic nuclear medicines is expected to grow at a 9.7% annual rate, and maximum adoption is estimated by cancer research institutes at a global level.

• North America, jointly with Western Europe, represents more than 65% share of the total market value.
• Outpacing developed regional markets, the radiopharmaceuticals market in China and emerging economies across Asia Pacific, Latin America, and Middle East & Africa are slated for higher year on year revenue growth of over 12% in 2019 and ahead.
• China is reportedly the most lucrative market for penetration of therapeutic nuclear medicines, which is attributed to an expanding cancer patient pool in the country and a consistently surging rate of radiopharmaceuticals recommendation.

Request For Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2930

Top Three Companies Account for More than 87% Market Value Share

A highly consolidated marketplace, global therapeutic nuclear medicines landscape is dominated by Bayer AG that currently accounts for just-under 80% revenue share in market. The top three players include GE Healthcare and Novartis AG other than Bayer, which collectively cover over 87% of the total valuation of radiopharmaceuticals market. While exceptional sales and success rate of Xofigo have been prominently retaining Bayer’s top position in the global market, strategic acquisitions are identified to be the key strategy behind Novartis’ success at a global level.

Thorough assessment of the competitive landscape of global therapeutic medicines market reveals a few prominent developmental strategies adopted by a majority of key companies operating in radiopharmaceuticals landscape –

• Investments in R&D of targeted cancer therapeutics
• Stronger supply chain and more streamlined distribution network
• Improved flagship product sales
• Strategic collaborations with pharma/biopharmaceutical companies
• Contractual relationships with domestic/regional stakeholders
• Strategic deals with internationally recognized cancer research institutes

Therapeutic Nuclear Medicines Market

Over 20% Growth Forecast for Erbium-169

Radium-223 has been the highest recommended type of radionucleotide in radiopharmaceuticals market. While it currently accounts for a whopping 78% share in the global market revenue, it is more likely that Erbium-169 that has been witnessing higher traction in recent past would witness relatively higher revenue growth in coming years. The report forecasts over 20% year on year revenue growth for Erbium-169 in 2019.

Exceptional Growth Projections for Thyroid & Brain Cancer

While over half the global market value is accounted by the adoption of therapeutic nuclear medicines for treatment of prostate cancer, bone metastases also accounts for sizable revenue generation in the market. Brain tumor and thyroid cancer are likely to emerge highly lucrative targets for manufacturers of therapeutic nuclear medicines, according to the report.

Get TOC @ https://www.futuremarketinsights.com/reports/therapeutic-nuclear-medicines-market/table-of-content

Table of Content

1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

1. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

2.3. Exclusion and Inclusion

1. Global Economic Outlook

3.1. Gross Domestic Product by Country, 2006 – 2021

3.2. Global Pharmaceutical Market Overview

1. Market Opportunity Analysis

4.1. Macro-Economic Factors

4.2. Opportunity Analysis

1. Market Dynamics

5.1. Drivers

5.1.1. Supply Side Drivers

5.1.2. Demand Side Drivers

5.2. Restraints

5.3. Trends

1. Key Inclusion

6.1. Parent Market Analysis

6.2. Key Regulation

6.3. Reimbursement Scenario

6.4. Pipeline Assessment

6.5. Disease Epidemiology

According to a recent study published by National Center for Biotechnology Information (NCBI) in May 2020, the overall prevalence of onychomycosis was approximately 5.5% in the general population.

The prevalence of onychomycosis has been increasing over the past few years due to unhealthy lifestyle and negligence of nail care. Future Market Insights (FMI) presents a positive outlook for the onychomycosis treatment market, forecasting it to exhibit 6.1% Y-o-Y growth in 2021.

Toenail onychomycosis are more common and requires longer duration of treatment, which can also extend to a year. Sometimes complete cure, defined as clinical cure, is unattainable, which may lead to indefinite treatment duration and consequently drive the onychomycosis treatment market. The risk of onychomycosis is 1.9 to 2.8 times higher in people with diabetes, compared with the general population. This is leading to rising revenue accumulation of drug manufacturers targeting the onychomycosis treatment market.

To remain ‘ahead’ of your competitors, request for a sample

The increasing risk factors such as nail injury or nail surgery, diabetes, weakened immune system, blood circulation disorders, athlete’s foot or ringworm, and others are driving the onychomycosis treatment market. The growing risk of occupational hazards such as agriculture, waste disposal, and others is also propelling the growth of the onychomycosis treatment market.

Diabetes and related conditions contributing to poor peripheral circulation are the major drivers of the market. Onychomycosis may represent an important forecast for the development of diabetic foot syndrome and foot ulcers. Patients who are immunosuppressed, such as those undergoing cancer therapy and those with HIV infection also are predisposed to fungal nail infection.

Coronavirus pandemic has changed the public medical care needs and spending however this is viewed as transient effect on the onychomycosis treatment market. The increasing COVID-19 patient pool attracted spotlight to the treatment of these patients on emergency basis, consequently reducing the patient visits to the medical clinics for onychomycosis treatment.

Decreasing visits demonstrate lesser treatment reception that resulted in temporary contraction of sales. Nonetheless, demand is likely to recover in the coming years with drugs emerging as more preferred type of treatment. The drugs segment is expected to account for nearly 75% of revenue generated in the market.

Key Takeaways from Onychomycosis Treatment Market Study

• High spending power supports growth in the U.S., sealing its dominance in North America. The U.S. is expected to account for over 84% of sales registered in the region
• The demand from the U.K. will continue rising, enabling year-on-year growth at above 7%
• Germany and France too will continue exhibiting high demand
• Within East Asia, Japan holds dominance, yet demand from China is likely to rise at a higher pace

“Market players are likely to focus on merger and acquisition to expand their footprint worldwide. They are also expected to focus on capitalizing on opportunities across emerging economies to gain competitive advantage,” said an FMI analyst.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1279

Geriatric Population More Susceptible Onychomycosis

According to the World Health Organization (WHO), age is the key risk factor for the development of onychomycosis and the risk for onychomycosis increases with age, particularly for persons aged >50 years. Approximately, about 80-85% of onychomycosis occurs in patients aged greater than 50 years, globally. The rise in elderly population will therefore present lucrative growth opportunities to onychomycosis treatment market.

Who is Winning?

Key players in the onychomycosis treatment market are keenly focusing on strategic activities such as acquisitions, collaborations and mergers in order to create a strong position.

For Instance, In September 2018, Almirall S.A. acquired of portfolio of five products comprising of Allergan’s Medical dermatology unit in the U.S. to further enhance the company’s dermatology portfolio.

In 2017, Ziarco Group ltd. was acquired by Novartis acquired. Ziarco Group ltd. a privately held company in the U.K. The company focuses on the development of novel treatments in the field of dermatology.

Key Players

• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Medimetriks Pharmaceuticals, Inc.
• Galderma
• Johnson & Johnson
• Novartis AG
• Moberg Pharma AB
• Cardinal Health, Inc.
• Pfizer Inc.
• Almirall, S.A.
• Bayer AG
• Viatris Inc.
• GlaxoSmithKline plc
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd

Onychomycosis Treatment Market by Category

Treatment Type

• Drugs
  • Oral
    • Rx
    • OTC
  • Topical
    • Rx
    • OTC
• Lasers
  • C02 Ablative Lasers
  • Nd:YAG Lasers
  • Dual-wavelength near-infrared Lasers
• Photodynamic Therapy

Disease Indication

• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

Age Group

• 0-18 Years
• 18-39 Years
• 40-64 Years
• 65 Years & Above

Gender

• Male
• Female

Distribution Channel

• Institutional Sales
  • Hospitals
  • Dermatology Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1279

Region

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa (MEA)

Rapidly improving healthcare infrastructure and reimbursement scenario has been a major booster for the healthcare industry in developing regional markets. With incessantly increasing number of cancer cases, it is more likely that the subsequent demand for a wide range of treatments adopted to treat cancer patients would also remain on a constant rise over the course of coming years.

Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.

A new market research study on global radiation-induced myelosuppression treatment forecasts steady growth for the market in the next few years. Future Market Insights projects a moderate, just-under 4% yearly growth outlook, in 2019 and ahead.

Nutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opporunities for radiation-induced myelosuppression treatment providers.

Report tracks key factors driving revenue growth of the market –

• Increasing prevalence of cancers
• Early diagnosis, promising improved chances of positive outcomes
• Fostering R&D funds supporting cancer research
• Strong product pipeline
• Bolstering adoption of chemo-radiotherapy in cancer treatment

Any Queries, Ask us @ https://www.futuremarketinsights.com/ask-question/rep-gb-8116

In the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.

• Myelo001 by Myelo Therapeutics GmbH recently received an FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.
• Mylan NV and Pfizer Inc. also reveived FDA approvals for their recently launched biosimilars – Epogen and Neupogen, and Neulasta respectively.

Patent expiry of originator biologics formulations is creating investment opportunities in biosimilars production – for the operators in radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.

Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the radiation-induced myelosuppression treatment market in the region. North America will reportedly continue to account for over 65% share in the global market value.

Get Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

New product launches currently mark the top developmental strategy adopted by leading companies competing in the radiation-induced myelosuppression treatment market. A majority of key players are also identified to focus on enhancing their geographical foothold in global radiation-induced myelosuppression treatment landscape.  The report in a distinct section covers some of the key competitors operating in radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.

A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.

In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, in an effort to achieve better penetration into regional markets.

Buy Industry Research Report @ https://www.futuremarketinsights.com/checkout/8116

Growing use of antibiotics in treating even the most common health conditions remains a strong factor boosting demand for antibiotic susceptibility testing (AST). Increasing government funds for microbial and antibiotic susceptibility testing research and consistently improving outcome of PPPs in terms of enhanced screening and evaluation of antibiotics are playing a pivotal role in strengthening the performance of antibiotic susceptibility testing market. CDC’s ‘AMR Challenge’ involving bioMérieux is a recently announced as objective to accelerate research efforts in the field of microbial resistance.

Nearly 70% of the psoriasis patient population is prone to psoriatic arthritis, and up to 20% of arthritis patients are susceptible to acquire psoriasis, according to the recent findings of the Arthritis Foundation.

The rate of increasing burden of psoriasis and psoriatic arthritis on healthcare industry has been boosting clinical research in the field of psoriatic arthritis, in recent years.

Sustained adoption of conventional disease modifying anti-rheumatic drugs (DMARDs), especially in cost sensitive regions, is projected to push the demand for psoriatic arthritis treatment in coming years.

Psoriatic Arthritis (PsA) Treatment Market – Key Research Findings

Global Psoriatic Arthritis (PsA) treatment market size in 2018 – nearly US$ 7,800 Mn.

The Psoriatic Arthritis (PsA) treatment market is expected to grow at an approximate CAGR of 7.2% over 2018-2028.

North America and Europe are expected to remain the largest regional markets for Psoriatic Arthritis (PsA) treatment

North America and Europe are among the prominent regions in the Psoriatic Arthritis (PsA) treatment market owing to the increasing adoption of biologics and biosimilars, along with the growing adoption of combination treatment for psoriatic arthritis.

To remain ‘ahead’ of your competitors, request for a sample

Prominent Players:

Pfizer Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Services
Inc.
AbbVie Inc.
Amgen Inc.
Novartis AG
AstraZeneca Plc UCB S.A.
Eli Lilly & Co
and Celgene Corporation

Role of Strong Product Pipeline & Mounting Clinical Research Investments

Over 20 drugs for psoriasis and psoriatic arthritis are currently in the phase II of pipeline, whereas more than 28 are in phase III of clinical trial, as indicated by the National Psoriasis Foundation. However, around 24 drugs have already received FDA approval for inclusion in the treatment for psoriasis and psoriatic arthritis.

While such a strong product pipeline continues to drive the demand for psoriasis and psoriatic arthritis treatment, a new research points to the shifting focus of several drug manufacturers to competitive pricing strategies, in an effort to attain widespread acceptance in coming years. Recently, Future Market Insights released a new intelligence based on the analysis of global psoriatic arthritis treatment market. The study forecasts a robust over-7% yearly growth for the market in 2019.

Industry Behemoths Cover More than 55% Market Value Share

In a fairly consolidated global landscape of psoriatic arthritis treatment market, more than 55% share of the total revenue is accounted by industry giants such as Novartis AG and AbbVie Inc. that include biologics in their core portfolio. While market leaders are maintaining focus on FDA approvals and clinical trials, research also points to the increasing importance of diverse pricing strategies.

Moreover, prominent players in psoriatic arthritis treatment market are likely to augment investments in R&D of biosimilars, biologics, and TNF (tumor necrosis factor) inhibitors to target regional markets. A number of leading drug manufacturers are also maintaining sizable investments in DMARDs that are scheduled for market entry in next few years. This is perceived as a strong factor improving growth prospects of psoriatic arthritis treatment market, according to the report.

Besides all these, strategic acquisitions, partnerships, and collaborations will remain the preferred expansion strategies adopted by a majority of prominent operators in psoriatic arthritis treatment landscape,” says a senior research analyst at the company.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-2718

Demand for Biologics & DMARDs Gaining Momentum

Research-driven understanding of the pathophysiology of psoriatic arthritis is fueling the introduction of innovative therapies in psoriatic arthritis treatment market, triggering innovations among the market participants – thereby supporting the growth of psoriatic arthritis treatment market. Targeted biological therapy has been demonstrating a decent success rate in terms of inducing temporary pain relief resultant of psoriatic arthritis, and thus continues to represent an attractive position in the psoriatic arthritis treatment market.

The report says that the demand for biologics accounts for more than 55% share of the global market revenue, whereas DMARDs demand makes up for more than 3/4th of the total market value. Although a majority of psoriatic arthritis patients opt for injectable as a preferred route of administration of psoriatic arthritis treatment, increasing introduction of innovative oral drugs is uplifting the popularity of orally administered psoriatic arthritis treatment.

Development of novel oral treatments for psoriatic arthritis is likely to favor the growth of North America’s market. Growing availability of combination therapies and relatively economical biosimilar antibody therapeutics are identified to be the primary boosters for the growth of Europe’s market. Collectively, North America and Europe account for over 60% share in the global value of psoriatic arthritis treatment market. The report indicates that the psoriatic arthritis market in Asia Pacific is likely to display high growth potential in the course of next few years.

PSORIATIC ARTHRITIS (PSA) TREATMENT MARKET TAXONOMY

The global psoriatic arthritis (PsA) treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Product

Non-steroidal anti-inflammatory drugs

Disease modifying Anti-rheumatic drugs

Corticosteroids

Antimalarial

Methotrexate

Others

Biologics

TNF Inhibitors

Interleukin inhibitors

By Route of Administration

Oral

Injectable

By Distribution Channel

Hospital pharmacies,

Retail pharmacies,

Mail order pharmacies

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-2718

Region

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East & Africa

Rising prevalence of endometriosis condition has fueled the demand for endometriosis treatment across the world. High focus on the introduction of therapeutically-advanced endometriosis treatment options are expected to propel the growth of the market over the forecast period. Leading industry players are significantly accelerating the development of scientific and clinical therapeutic agents and new product launches in the global endometriosis treatment market. This considerable push by industry players is expected to drive future market growth.

The 3D cell culture market revenues surpassed US$ 778 million in 2018, as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

• A steady rise in global research and development expenditure
• Efforts to leverage the potential of 3D cell culture to replace animal model testing
• Increasing demand for biosimilar products
• Extensive application of stem cell research and a growing emphasis on regenerative medicine

“While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years,” says FMI.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-2843

The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold free 3D cell culture. Owing to a significant adoption of scaffold-based 3D cell culture, study finds that this techniques garnered over 81% of the global market revenues.

Scaffold based 3D cell culture techniques deliver researchers with additional functional operations in terms of material – natural or synthetic and different mechanical properties.

The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.

According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.

Buy this report: https://www.futuremarketinsights.com/checkout/2843

Application of 3D Cell Culture in Cancer Research Prominent

The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.

2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.

Stem cell technology is another lucrative field for 3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine and drug discovery.

Preview Analysis of 3D Cell Culture Market is segmented by (Product type – scaffold-free 3D cell culture & scaffold-based 3D cell culture; Application – drug discovery, tissue regeneration & regenerative medicines, cancer research, stem cell technology, and others; End user – biotechnology and pharmaceuticals industries, hospital laboratories, academic research and institutes, and contract research organizations;) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028: https://www.futuremarketinsights.com/reports/3d-cell-culture-market

Biotechnology and Pharmaceutical Industries – Prominent End-Users

The study reveals that the biotechnology and pharmaceutical industries were accounted for over one-fifth of the global 3D cell culture market revenues in 2018. Buoyancy in the biotechnology and pharmaceutical industries can be profitable for the 3D cell culture market in the coming years and over 9% growth is projected in 2019 over 2019.

Academic research institutes are the second prominent end-users of 3D cell cultures wherein they accounted for over one-fourth of the global 3d cell culture revenues in 2018. Government funding in cancer research projects carried out at academic institutes and organizations has increased significantly, thereby supporting the investments in advanced technologies including 3D cell culture techniques.

Revenues in North America Continue to Surge

North America continued to spearhead the revenues of 3D cell culture market during the historical period and the status-quo is likely to continue in the future. In 2018, North America accounted for over two-fifth of the global 3D cell culture market revenues. The study estimates that regional revenues are expected to grow at 8% in 2019 over 2018.

Funding in research and development, especially in cancer research remains higher in the United States as compared to other developed countries. Europe also presents significant funding in R&D activities. The FMI study finds that over one-fourth of the 3D cell culture market revenues were accounted for the Europe region in 2018, of which a bulk of revenues come from Western European countries such as Germany, the UK, France, Italy and Spain.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-2843

The brain monitoring systems market is projected to expand at a healthy pace with global sales exceeding US$ 3.5 Bn by end of 2019, as per the latest research study by FMI. A range of broad factors, including the government funding for development of advanced medical devices, and favorable healthcare reimbursements are key sales influencers of brain monitoring devices.

The FMI report finds that rising prevalence of brain aneurysm and chronic brain injuries have necessitated adoption of brain monitoring systems expediting early and effective treatment. According to the Brain Aneurysm Foundation, nearly 6 million individuals in the U.S. suffer from unruptured brain aneurysm. In the wake of such alarming statistics, the adoption of brain monitoring systems is surging at an impressive rate for revolutionizing patient care.

As per the study, demand for brain monitoring systems significantly took off in parallel with convergence of technology and healthcare, which translated into a massive influx of advanced medical devices with high functionality.

“Rising inclination toward non-invasive procedures is inducing a shift toward devices facilitating seamless observation and identification of neurons without involvement of invasive neurosurgery, such as brain monitoring systems,” says FMI report

To remain ‘ahead’ of your competitors, request for a sample

The study opines EEG machines to gain significant momentum as widely-preferred brain monitoring systems, with revenues estimated to surpass US$ 1.5 Bn in 2019. Focus on delivering effective treatment via early detection of abnormalities have led the adoption of EEG machines, as these enable beneficial interventions with minimum chances of neurological complications. Simple platforms, effective report generator, and streamlined assessment tools are key attributes of EEGF machines that have driven their preference among patients and physicians alike.

Brain monitoring systems continue to witness significant demand from Hospitals (ICUS and adult care), with revenue expected to cross US$ 1 Bn in 2019. In response to high demand from hospitals, EEG machine manufacturers are implementing novel product development strategies, to realize enhanced profit margins.

Convergence of IOT with Brain Monitoring Space – A Key Trend Fostering Functionality with Better Connectivity

Penetration of IoT in the medical devices and systems landscape shows no signs of abating, evolving as a promising breakthrough that could result in connected ecosystems for brain monitoring devices with enhanced functionalities. IoT continues to play a major role in redefining interactions among various components of a brain monitoring system, thereby resulting in reduced costs, improved outcomes, and enhanced patient experiences. This trend is further complemented by on-going research efforts by prominent universities. For instance, a cohort of researchers at the Wits University of South Africa developed a way to connect human brains with internet on a real-time basis.

The transition toward miniaturized and portable models is gaining swift momentum in the brain monitoring systems landscape, as patients actively seek for advanced devices with new modalities, such as Functional Near-Infrared Spectroscopy (fNIRS), which enable real-time monitoring. The research study by FMI finds that future adoption of such upgraded versions will remain significant among physicians, as these facilitate seamless capture, storage, and processing of neurological information.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-1259

Major players are making headway with strategic partnerships, acquisitions, and mergers to attain competitive advantages and access a wide-range range of resources and expertise. For instance, Philips acquired Electrical Geodesics, Inc. in 2017 with an objective to establish a new integrated neurological imaging, mapping and therapy guidance portfolio. Partnerships as such are foreseen to help in organic growth of the market players via collaborative innovations.

The FMI report covers assessment and forecast of the brain monitoring systems market for the period of 2018 to 2028. According to the report, the brain monitoring systems market is expected to grow at a CAGR of over 6% through 2028.

Competitive Landscape

This section of the report features profiles of key players operating in the brain monitoring systems market based on their market shares, differential strategies, brain monitoring systems product offerings, marketing approach and company dashboard.

Examples of some of the key players featured in this report include

Nihon Kohden Corporation., Electrical Geodesics, Inc. (Koninklijke Philips N.V.), Siemens Healthcare GmbH, Hitachi Ltd Natus Medical Incorporated, Medtronic plc. Compumedics Ltd, Neurosoft, EB Neuro S.p.A, and Ricoh Company Ltd among others.

The key manufacturers of brain monitoring systems are focusing on marketing strategies to increase both their product portfolio as well as geographical presence. The company’s manufacturing brain monitoring systems are focused on pricing strategies in order to lead in the market for brain monitoring systems.

Some other key market strategies followed by brain monitoring systems manufacturers include distribution & collaboration agreements to increase product reach, partnering with local as well as global retailers, and long-term partnerships with ambulatory surgical centers, clinics, hospitals and other distributor channels such as neonatal and pediatrics ICUs

Key Segment

Based on product type

fNIRS

EEG Systems

MEG Systems

MRI Systems

other brain monitoring systems

Based on modality

Portable/Handheld Systems

Standalone Systems

Based on end-users

hospitals

ambulatory surgical centers

clinics

pediatric & neonatal intensive care units

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1259

Based on region

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

China

Japan

MEA

Retinal biologics market value surpassed US$ 14.6 billion in 2018 and projected to grow at 10.7% y-o-y in 2019, as per a new FMI study. The projected growth of the market can be attributed to,

A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a subdued 3% y-o-y in 2019. Valued at nearly US$ 7 billion in 2018, gains are likely to be driven by a combination of multipronged factors, including,

• Development of natural product interventions for chemotherapy-induced side effects
• Growing implementation of radiation treatment in cancer treatment owing to the associated high success rate of chemotherapy
• Growing R&D investments in cancer research

The FMI study finds that ‘growth factor’ drugs continued to garner highest revenues in the chemotherapy-induced myelosuppression treatment market. In 2018, over 73% of the chemotherapy-induced myelosuppression treatment market revenues were consolidated in the growth factors. Gains were especially notable for granulocyte-colony stimulating factor or G-CSF, which accounted for over 60% of the global chemotherapy-induced myelosuppression treatment market revenues in 2018.

The FMI study reveals that erythropoietin-stimulating agents (ESA) also accounted for a significant market share, with revenues likely to grow at 2.8% in 2019. In April 2017, FDA announced the removal of risk evaluation and mitigation strategy (REMS) requirement for the use of ESA drugs in myelosuppression treatment. The ESAs used in the treatment of radiation-induced myelosuppression treatment are epoetin alfa and darbepoetin alfa. This has led healthcare professionals to engage in the practice of discussing benefits as well as risks of treatments that include ESAs before initiating the use.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1364

Hematopoietic growth factors have transformed the practice of cancer treatment by allowing stimulation of production of specific cells. With this, use of thrombopoietin receptor agonists is expected to rise rapidly at the rate of 3.5% in 2019.

Injectable Drugs Present Higher Therapeutic Availability over Orals

The FMI study finds that injectable drugs accounted for over 97% of the chemotherapy-induced myelosuppression treatment market revenues in 2018. The status-quo will continue in the future, however, the oral route of administration is expected to garner increasing annual revenues and expected to grow at 4.8% in 2019 over 2018.

Increasing number of research validations related to the benefits of the oral route of administration can be attributed to the higher growth rate of the segment in the future. However, revenues from the injectable route of the administration continue to grow steadily on the back of their higher therapeutic availability over orally administered drugs.

Market Revenues Consolidated in Neutropenia Treatment

According to the study, chemotherapy-induced myelosuppression treatment market revenues heavily consolidated in the neutropenia treatment. In 2018, neutropenia indication accounted for over 62% of market revenues. As neutropenia is one of the most common side effects of chemotherapy wherein prolongation of the same can lead to life-threatening infections. Owing to the severity of the implications, chemotherapy-induced myelosuppression therapeutics are heavily used in the treatment of neutropenia.

Anemia and thrombocytopenia indications also utilize chemotherapy-induced myelosuppression treatment therapeutics. The study finds that revenues in the thrombocytopenia treatment will grow at 3.7% y-o-y in 2019.

Preview Analysis On Global Chemotherapy-Induced Myelosuppression Treatment Market Segmentation by By Drug Class (Growth Factors, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonists, Erythropoietin-stimulating Agents, Thrombopoietic Agents, Iron supplementation, Others); By Route of Administration (Oral, Injectable); By Indication (Anemia, Neutropenia, Thrombocytopenia): https://www.futuremarketinsights.com/reports/chemotherapy-induced-myelosuppression-treatment-market

Retail Pharmacies Most Prominent Sales Channel

The study opines that chemotherapy-induced myelosuppression treatment therapeutics sales remain higher through retail pharmacies. Suppliers of these therapeutics have extensive distribution network with international retail pharmacies. Due to this, retail pharmacies accounted for over 48% of the chemotherapy-induced myelosuppression treatment market revenues in 2018.

Owing to heavy integration of pharmacies in the hospitals, distribution of chemotherapy-induced myelosuppression treatment therapeutics through hospital pharmacies also account for a considerable share of the market revenues. The study finds that hospital pharmacies can be called the second largest distributor of chemotherapy-induced myelosuppression treatment therapeutics owing to their 45% of the market revenues.

Additional Questions Answered

Some of the additional questions addressed in this report on the chemotherapy-induced myelosuppression treatment market:

• What is the overall revenue generation potential of the chemotherapy-induced myelosuppression treatment market across the regions of Europe and Asia-Pacific?
• Who are the key regional and global competitors? What are their portfolios in the chemotherapy-induced myelosuppression treatment market?
• What are the major challenges influencing the growth of the chemotherapy-induced myelosuppression treatment market?